Pew Funds Genetics and Public Policy Center's New Consumer Genetics Project
The Pew Charitable Trust has awarded $750,000 to the Genetics and Public Policy Center for a new project focused on consumer protections for applications of genetic testing.
The Human Genome Project unleashed a torrent of information about the human genome and the role of genetic variation in human health. As a result, genetic testing is now among the fastest growing areas of laboratory medicine. Today, genetic tests for about 1000 diseases are clinically available, with hundreds more available in a research setting.
The Genetics and Public Policy Center’s survey assessed laboratory directors’ attitudes toward laboratory quality and oversight. Nearly all directors found proficiency testing to be very or somewhat useful in improving the quality of genetic testing (23) (Figure 5). A majority (73 percent) of those surveyed agreed or strongly agreed that CLIA should create a genetic testing specialty for molecular and biochemical tests (23) (Figure 6).
While the regulated industry supports the creation of a genetic testing specialty under CLIA, the College of American Pathologists, which accredits clinical laboratories and administers proficiency testing, consistently has opposed the creation of a genetic testing specialty (47-49).
Those who have the most to gain or lose from the accuracy and reliability of genetic testing — that is, patients — resoundingly have expressed their support for the creation of a genetic testing specialty. In February 2006, the Genetic Alliance sent a letter to CMS Administrator Mark McClellan urging him to issue a proposed rule for a genetic testing specialty under CLIA, stating that a specialty “is a necessary first step toward a regulatory system that encourages new technology and ensures safety and accuracy when those technologies are implemented.”(33)
A diverse array of stakeholders also has supported a genetic testing specialty under CLIA. In June 2006, a letter signed by 75 groups comprising patient advocacy organizations, genetic testing laboratories, healthcare provider organizations, and industry urged CMS to issue a proposed rule for a specialty (50). Separately, 14 women’s health advocacy organizations also wrote CMS asking for creation of a genetic testing specialty (51).

1. Public Law 100-578 (1988), codified at U.S. Code, 42, § 263a.
2. U.S. Congress. Senate. Special Committee on Aging. At Home DNA Tests: Marketing Scam or Medical Breakthrough? 109th Cong., 2d sess., 2006 (Testimony of Thomas Hamilton).
3. 2005. How Reliable is Laboratory Testing? American Association for Clinical Chemistry. http://www.labtestsonline.org/understanding/features/reliability.html (accessed August 23, 2006).
4. 2003. International Consortium Completes Human Genome Project. NHGRI. http://www.genome.gov/11006929 (accessed August 23, 2006).
5. GeneTests. University of Washington. www.genetests.org (accessed August 23, 2006).
6. Guttmacher, A. E. and F. S. Collins. 2005. Realizing the promise of genomics in biomedical research.Journal of the American Medical Association 294 (11): 1399-402.
7. Guttmacher, A. E. and F. S. Collins. 2002. Genomic medicine - a primer. The New England Journal of Medicine 347 (19): 1512-20.
8. Marsh, S. and H. L. McLeod. 2006. Pharmacogenomics: From bedside to clinical practice. Human Molecular Genetics 15 (Review Issue 1): R89-R93.
9. Holtzman, Neil and Michael Watson, eds. 1997. Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing. NHGRI. http://www.genome.gov/10001733 (accessed August 23, 2006).
10. 2000. Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT. National Institutes of Health. http://www4.od.nih.gov/oba/sacgt/reports/oversight_report.pdf (accessed August 23, 2006).
11. Institute of Medicine. Assessing Genetic Risks: Implications for Health and Social Policy (Lori B. Andrews, Jane E. Fullarton, Neil A. Holtzman, Arno G. Matulsky, eds.). 1994.
12. Clinical Laboratory Improvement Advisory Committee Meeting Summary Reports February 7-8, 2001, January 30-12, 2002, September 11-12, 2002, September 17-18, 2003, February 11-12, 2004, September 22-23, 2004, February 16-17, 2005, September 7-8, 2005, and February 8-9, 2006. http://www.phppo.cdc.gov/dls/cliac/default.asp (accessed August 27, 2006).
13. Federal Register 65 (May 2000): 25928.
14. Federal Register 71 (April 2006): 22595.
15. Meeting between representatives of the Genetics and Public Policy Center and representatives of the Centers for Medicare and Medicaid Services, August 3, 2006.
16. Rivers P. A., et al. 2005. A review and analysis of the Clinical Laboratory Improvement Amendment of 1988: compliance plans and enforcement policy. Health Care Management Review 30 (2): 93-102.
17. House Committee on Energy and Commerce, Clinical Laboratory Improvement Amendments of 1988, 100th Cong., 2nd sess., 1988, H. Rep 100-899.
18. Code of Federal Regulations, title 42, sec. 493. References Public Health at Risk: Failures in Oversight of Genetic Testing Laboratories 21
19. Code of Federal Regulations, title 42, sec. 493.17.
20. Code of Federal Regulations, title 42, sec. 493.15.
21. Code of Federal Regulations, title 42, sec. 493.801.
22. Code of Federal Regulations, title 42, sec. 493.801(a)(2)(ii).
23. Hudson, K., et al. 2006. Oversight of U.S. genetic testing laboratories. Nature Biotechnology 24 (9): 1083-1090.
24. Murphy, Juli, Gail Javitt, and Kathy Hudson. 2005. Creating a Genetic Testing Specialty under CLIA: What are we waiting for? Genetics and Public Policy Center. http://www.dnapolicy.org/resources/McClellanpaper.pdf (accessed August 23, 2006).
25. Javitt, Gail pers. comm. to Judy Yost, July 15, 2005.
26. Yost, Judith pers. comm. to Gail Javitt, September 15, 2005.
27. Hudson, Kathy pers. comm. to Mark McClellan, November 18, 2005.
28. Hamilton, Thomas pers. comm. to Kathy Hudson, Jan. 9, 2006.
29. Testimony of Judith A. Yost, director, Division of Laboratory Services, Centers for Medicare and Medicaid Services, before the Secretary’s Advisory Committee on Genetics, Health, and Society, June 26, 2006.
30. 2006. Nutrigenetic Testing: Tests Purchased From Four Websites Mislead Consumers. United States Government Accountability Office. http://www.gao.gov/new.items/d06977t.pdf (accessed August 23, 2006).
31. Federal Register 68 (January 2003): 3639
32. 2006. Practices and Attitudes of Laboratory Directors of Clinical Genetic Testing Laboratories. Johns Hopkins IRB No. NA-00001533. Unpublished data on file with Genetics and Public Policy Center, Washington, D.C.
33. Terry, Sharon pers. comm. to Mark McClellan, February 28, 2006.
34. Smith, Dennis pers. comm. to Sharon Terry, July 17, 2006.
35. Schirmer v. Mt. Auburn Obstetrics and Gynecological Associates, 844 N.E.2d 1160 (2006).
36. Hood v. Lab. Corp. of Am., 2006 U.S. Dist. LEXIS 36464 (D.Md. 2006)
37. Libby, E. N., et al. 2006. False-negative factor v Leiden genetic testing in a patient with recurrent deep vein thrombosis. American Journal of Hematology 81: 284-289.
38. Our stories. Matthew Forbes Romer Foundation. http://www.mfrfoundation.org/stories.php (accessed August 29, 2006).
39. Feiger, J. 2003. Protecting patients while managing lab errors. Perspectives in Genetic Counseling. 25 (3): 4 22 Public Health at Risk: Failures in Oversight of Genetic Testing Laboratories
40. Hofgartner, W.T. and J.T. Tait. 1999. Frequency of problems during clinical molecular genetic testing. American Journal of Clinical Pathology 112: 14-21.
41. Bonini P. et al., 2002. Errors in laboratory medicine. Clinical Chemistry 48 (5): 691-698.
42. Witte, D. L. et al. 1997. Errors, mistakes, blunders, outliers, or unacceptable results: how many? Clinical Chemistry 43 (8): 1352-1356.
43. Howanitz, P. J. 2005. Errors in laboratory medicine: practical lessons to improve patient safety. Archives of Pathology & Laboratory Medicine 129: 1252-1261.
44. Hollensead, S. C., et al. 2004. Errors in pathology and laboratory medicine: consequences and prevention. Journal of Surgical Oncology 88: 161-181.
45. McGovern, M. M., et al. 1999. Quality assurance in molecular genetic testing laboratories. Journal of the American Medical Association 281 (9): 835-840.
46. 2006. Standards and Guidelines for Clinical Genetics Laboratories. American College of Medical Genetics. http://www.acmg.net/Pages/ACMG_Activities/stds-2002/stdsmenu-n.htm (accessed August 23, 2006).
47. Bachner, Paul, pers. comm. to Joe Boone, June 28, 2000.
48. Clinical Laboratory Improvement Advisory Committee Meeting Summary Report, September 10, 1997. http://www.phppo.cdc.gov/dls/cliac/default.asp (accessed August 30, 2006).
49. The Secretary’s Advisory Committee on Genetics, Health, and Society’s Summary of Third Meeting, March 1-2, 2004, pages 6-7 (public comments of Margaret Gulley, MD, College of American Pathologists). http://www4.od.nih.gov/oba/sacghs/meetings/March2004/SACGHS (accessed August 30, 2006).
50. Terry, Sharon, et al. pers. comm. to Mark McClellan, June 6, 2006.
51. Reproductive Health Technologies Project, et al. pers. comm. to Mark McClellan, July 13, 2006.
52. Frost and Sullivan, U.S. Genetic Diagnostics Markets, Market Report F463-52, 2005.
53. Meeting summaries of the Clinical Laboratory Improvement Advisory Committee. http://www.phppo.cdc.gov/dls/cliac/default.asp (accessed August 30, 2006).
54. Shalala, D. pers. comm. to Ed McCabe, January 19, 2001. http://www4.od.nih.gov/oba/sacgt/McCabe.pdf (accessed August 30, 2006).
The Pew Charitable Trust has awarded $750,000 to the Genetics and Public Policy Center for a new project focused on consumer protections for applications of genetic testing.
The Genetics and Public Policy Center’s Public Consultation Project on Genes, Environment, and Health consisted of focus groups, interviews with community leaders, a survey, and a series of town halls. This report summarizes the five town hall sessions, which took place from March-May 2008 in Jackson, Mississippi; Kansas City, Missouri; Philadelphia, Pennsylvania; Phoenix, Arizona; and Portland, Oregon.
Four in five Americans support the idea of a nationwide study to investigate the interactions of genes, environment and lifestyle, and three in five say they would be willing to take part in such a study, according to a survey released today.
More infoPresident Bush today signed into law the Genetic Information Nondiscrimination Act of 2008 (GINA), providing vital protection for Americans against the misuse of genetic test results by heath insurers and employers.
No mechanism currently exists to ensure that genetic tests are supported by adequate evidence before they go to market, or that marketing claims are truthful and not misleading, according to a policy analysis to be published April 4 in Science. Misleading claims about genetic tests may lead health-care providers and patients to make inappropriate decisions about which tests to take and how to use genetic tests that have potential for profound medical consequences, the authors argue.